You are here

SUBSCRIBERS

Roche drug cocktail doubles chance of holding lung cancer at bay

Zurich

ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.

Thirty-seven per cent of patients in a closely watched clinical...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes